Saturday, October 5, 2024

Press Release: National Cancer Institute Selects ICF for Epidemiology and Genetics Research IDIQ

The National Institutes of Health (NIH) National Cancer Institute’s (NCI) Division of Cancer Epidemiology and Genetics (DCEG) recently selected global consulting and digital services provider ICF (NASDAQ:ICFI) as one of five awardees for a new multiple-award indefinite delivery, indefinite quantity (IDIQ) contract to provide epidemiologic and clinical operations support for studies and other research activities.

The IDIQ, which was awarded in the second quarter of 2022, has a ceiling value of $320 million across all awardees and term of 10 years, including a five-year base and a five-year option period…

“ICF has a long history of supporting NIH’s epidemiologic and clinical research programs with technical expertise in scientific and survey research operations, statistical data management, digital modernization of data collection systems and more,” said Mark Lee, executive vice president and public sector lead. “We are excited to bring all of these skills to support DCEG in meeting its mission—to discover the causes of cancer and inform future prevention.”

For over 40 years, ICF has supported U.S. Department of Health and Human Services clients across all divisions with comprehensive services in public health, epidemiology, survey research, genetics, biostatistics, clinical informatics, digital modernization and more…

Read the full release here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

FedHealthIT Xtra – Find Out More!

Recent News

Don’t Miss A Thing

Jackie Gilbert
Jackie Gilbert
Jackie Gilbert is a Content Analyst for FedHealthIT and Author of 'Anything but COVID-19' on the Daily Take Newsletter for G2Xchange Health and FedCiv.

Subscribe to our mailing list

* indicates required